Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19

Phase 1 Withdrawn Sorrento Therapeutics, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19

Timeline

Start: 2020-09
Primary completion: 2021-01
Completion: 2021-01

Outcome

Outcome not reported

Stopped (Enrollment): “Difficulty recruiting”

Publications

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	COVI-GUARD	Monoclonal antibody	10 mg	Intravenous
Subject	COVI-GUARD	Monoclonal antibody	30 mg	Intravenous
Subject	COVI-GUARD	Monoclonal antibody	100 mg	Intravenous
Subject	COVI-GUARD	Monoclonal antibody	200 mg	Intravenous